NeVap Aspire Subglottic Suction Endotracheal Tube (ASSET)

The NeVap ASSET design offers several advantages over current devices:

  • 24 Suction fenestrations oriented so that vacuum is applied parallel to airway tissues.
  • Vacuum>100mm Hg can be applied continuous.
  • Higher pressures and continuous operation means improved removal of viscous fluids and reduced pooling and aspiration.
  • Designed to reduce respiratory care needs.
  • Superior Radiopaque confirmation of position and quieter operation.
  • Compliant with existing VAP prevention protocols.
  • No new clinician training.
  • No new capital equipment.
  • Designed by physicians for physicians.

Comparison to the Shiley Taperguard EVAC (Medtronic) in an ex-vivo trachea model:

single multi comparison

Additional Studies

The NeVap ASSET was shown to out-performed the Taperguard in a range of clinically significant settings, with  >90% of fluids at all challenge settings, under significant challenge conditions.

In 2018, clinical studies are planned with Kaiser Permanente, Sutter Health, UCSF, Hammersmith Hospital Health (UK) and the University of Miami.